Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Insamo logo — Pioneering the discovery of membrane-permeable and orally-av...

Insamo

Pioneering the discovery of membrane-permeable and orally-available cyclic-peptides with antibody-like binding affinity.

15 employees Seed Total: $12.00M Biotechnology, Life Sciences +1

General Information

Company Name Insamo
Employees 15
Industries Biotechnology, Life Sciences, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Insamo. To contact Insamo, visit insamo.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Insamo

Insamo is a biotechnology and pharmaceutical startup that is pioneering the discovery of membrane-permeable and orally-available cyclic peptides with antibody-like binding affinity. The company recently secured a significant milestone with a $12.00M Seed Round investment on 21st February 2024. This investment round was backed by an impressive lineup of investors including Civilization Ventures, Playground Global, Axial VC, MRL Ventures Fund, Sahsen Ventures, VenBio Partners, and BEVC. This substantial funding is a testament to the potential of Insamo's innovative approach and the confidence of prominent players in the industry. With this support, Insamo is well-positioned to advance its groundbreaking research and make waves in the biotechnology and pharmaceutical space.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $12.00M 7
Civilization Ventures Playground Global Axial VC
Civilization Ventures, Playground Global +5
21 Feb 2024

Insamo Alternatives & Competitors

View All Alternatives
Insamo vs
艾比玛特医药科技(上海)有限公司
艾比玛特医药科技(上海)有限公司

Empowering scientists with the future of antibody innovation and discovery.

Series B
4 employees
Biotechnology, Pharmaceutical
Insamo vs
Avilar Therapeutics
Avilar Therapeutics United States

Pioneering the discovery and development of extracellular protein degraders.

Seed
25 employees
Biotechnology, Pharmaceutical
Insamo vs
Corcept Therapeutics
Corcept Therapeutics United States

Pioneering the discovery and development of cortisol modulators.

Post-IPO Equity
798 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Insamo

Pioneering the discovery of membrane-permeable and orally-available cyclic-peptides with antibody-like binding affinity.
Insamo operates in Biotechnology, Life Sciences and Pharmaceutical.
Insamo has approximately 15 employees.
Insamo has completed 1 funding round, raising a total of $12.00M. The latest funding stage is Seed.
Top alternatives and competitors to Insamo include 艾比玛特医药科技(上海)有限公司, Avilar Therapeutics, Corcept Therapeutics, A&G Pharmaceutical, Inc., Sevion Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Insamo and 艾比玛特医药科技(上海)有限公司 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Insamo, https://bouncewatch.com/company/insamo, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes